Prolonged bisphosphonate release after treatment in children [18]

New England Journal of Medicine

Volumn 356, Issue 10, 2007, Pages 1075-1076

  Papapoulos, Socrates E ^a   Cremers, Serge C L M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

BONE DENSITY; BONE REMODELING; DISEASE SEVERITY; DRUG HALF LIFE; HUMAN; LETTER; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; URINALYSIS; URINARY EXCRETION;

EID: 33847734705     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc062792     Document Type: Letter

References (4)

1. Cremers SCLM, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005;44:551-70.
2. Brumsen C, Hamdy NAT, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton; studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997;76:266-83.
3. Landman JO, Hamdy NAT, Pauwels EKJ, Papapoulos SE. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 1995;80:3465-8.
4. Bone HG, Hosking D, Devogelaer J-P, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.